Interferon-γ Response by Peripheral Blood Mononuclear Cells to Hepatitis C Virus Core Antigen Is Reduced in Patients with Liver Fibrosis

Journal of Infectious Diseases

Volumn 188, Issue 10, 2003, Pages 1533-1536

  Watson, Mark W ^a,b   Jaksic, Aleksandra ^a,c   Price, Patricia ^a,b   Cheng, Wendy ^a   McInerney, Marian ^a   French, Martyn A ^a,b   Fisher, Scott ^a,b   Lee, Silvia ^a,b   Flexman, James P ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPATITIS C ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSTIMULATION; LIVER FIBROSIS; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS CORE;

ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 0346243725     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379252     Document Type: Article

References (13)

1. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351:351-5.
2. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24:759-65.
3. Lechmann M, Woitas RP, Langhans B, et al. Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol 1999; 31:971-8.
4. Scheuer PJ, Lefkowitch JH. Liver biopsy interpretation. 5th ed. London: Saunders, 1994.
5. Keane NM, Price P, Lee S, Stone SF, French MA. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol 2001; 126:111-6.
6. Anthony DD, Post AB, Valdez H, Peterson DL, Murphy M, Heeger PS. ELISPOT analysis of hepatitis C virus protein-specific IFN-gamma-producing peripheral blood lymphocytes in infected humans with and without cirrhosis. Clin Immunol 2001; 99:232-40.
7. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 296-305.
8. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25:449-58.
9. Del Prete G, De Carli M, D'Elios MM, et al. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med 1995; 182:1655-61.
10. Lee S, Macquillan GC, Keane NM, et al. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin. Immunol Cell Biol 2002; 80:391-7.
11. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12:227-57.
12. Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 1991; 12:17-23.
13. Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997; 159:1012-8.